JP4733350B2 - ケモカイン媒介疾患の併用治療 - Google Patents
ケモカイン媒介疾患の併用治療 Download PDFInfo
- Publication number
- JP4733350B2 JP4733350B2 JP2003577881A JP2003577881A JP4733350B2 JP 4733350 B2 JP4733350 B2 JP 4733350B2 JP 2003577881 A JP2003577881 A JP 2003577881A JP 2003577881 A JP2003577881 A JP 2003577881A JP 4733350 B2 JP4733350 B2 JP 4733350B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- alkyl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C(C(*)=C1*)=O)=C(*)N1O Chemical compound *C(C(C(*)=C1*)=O)=C(*)N1O 0.000 description 15
- HLPIHRDZBHXTFJ-UHFFFAOYSA-N CCc1ccc[o]1 Chemical compound CCc1ccc[o]1 HLPIHRDZBHXTFJ-UHFFFAOYSA-N 0.000 description 3
- JPBXKQARWDLKOL-HXUWFJFHSA-N CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O Chemical compound CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O JPBXKQARWDLKOL-HXUWFJFHSA-N 0.000 description 1
- OXZGQJVMTYTUMC-LJQANCHMSA-N CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2n[o]c(C)c2)=O)c1O Chemical compound CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2n[o]c(C)c2)=O)c1O OXZGQJVMTYTUMC-LJQANCHMSA-N 0.000 description 1
- GSTTYFZPWRSFNV-FQEVSTJZSA-N CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F Chemical compound CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F GSTTYFZPWRSFNV-FQEVSTJZSA-N 0.000 description 1
- RRRRXCOPMMELBR-RGUGMKFQSA-N CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)F Chemical compound CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)F RRRRXCOPMMELBR-RGUGMKFQSA-N 0.000 description 1
- MVRPGEKCCWFBCK-FQEVSTJZSA-N CC([C@H](c1ccc(C)[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F Chemical compound CC([C@H](c1ccc(C)[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F MVRPGEKCCWFBCK-FQEVSTJZSA-N 0.000 description 1
- BGZSEAUPZCITOQ-UHFFFAOYSA-N CCC1=CC=C(C)C1 Chemical compound CCC1=CC=C(C)C1 BGZSEAUPZCITOQ-UHFFFAOYSA-N 0.000 description 1
- WCTGQSUIVKIRPT-OAHLLOKOSA-N CCN(CC)S(c([s]cc1NC(C(C2=O)=O)=C2N[C@H](C(C)C)c2ccc(C)[o]2)c1O)(=O)=O Chemical compound CCN(CC)S(c([s]cc1NC(C(C2=O)=O)=C2N[C@H](C(C)C)c2ccc(C)[o]2)c1O)(=O)=O WCTGQSUIVKIRPT-OAHLLOKOSA-N 0.000 description 1
- DOGFHWZRKIHCNP-MRXNPFEDSA-N CC[C@H](c1cc(CC)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O Chemical compound CC[C@H](c1cc(CC)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O DOGFHWZRKIHCNP-MRXNPFEDSA-N 0.000 description 1
- OHMWIPJDIDNEDU-BZSJEYESSA-N CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)C2=NOC(C)C#C2)=O)c1O Chemical compound CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)C2=NOC(C)C#C2)=O)c1O OHMWIPJDIDNEDU-BZSJEYESSA-N 0.000 description 1
- YXUIAEFAARSCMI-MRXNPFEDSA-N CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O Chemical compound CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O YXUIAEFAARSCMI-MRXNPFEDSA-N 0.000 description 1
- NZHWONFZYMQAJN-UHFFFAOYSA-N CCc1cc(C(C)C)c[o]1 Chemical compound CCc1cc(C(C)C)c[o]1 NZHWONFZYMQAJN-UHFFFAOYSA-N 0.000 description 1
- SCHTWVSQHFFMTN-UHFFFAOYSA-N CCc1ccc(CSSc2ccccc2)[nH]1 Chemical compound CCc1ccc(CSSc2ccccc2)[nH]1 SCHTWVSQHFFMTN-UHFFFAOYSA-N 0.000 description 1
- XRPDDDRNQJNHLQ-UHFFFAOYSA-N CCc1ccc[nH]1 Chemical compound CCc1ccc[nH]1 XRPDDDRNQJNHLQ-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36531402P | 2002-03-18 | 2002-03-18 | |
| US60/365,314 | 2002-03-18 | ||
| PCT/US2003/008287 WO2003080053A1 (en) | 2002-03-18 | 2003-03-17 | Combination treatments for chemokine-mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533005A JP2005533005A (ja) | 2005-11-04 |
| JP2005533005A5 JP2005533005A5 (cg-RX-API-DMAC7.html) | 2010-05-27 |
| JP4733350B2 true JP4733350B2 (ja) | 2011-07-27 |
Family
ID=28454639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577881A Expired - Fee Related JP4733350B2 (ja) | 2002-03-18 | 2003-03-17 | ケモカイン媒介疾患の併用治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040053953A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1485089B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4733350B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100444839C (cg-RX-API-DMAC7.html) |
| AR (1) | AR040400A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003220384B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0308739A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2479126C (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04009127A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20044402L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ535314A (cg-RX-API-DMAC7.html) |
| TW (2) | TW200808314A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003080053A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200407339B (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| MXPA03009441A (es) * | 2001-04-16 | 2004-02-12 | Schering Corp | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc. |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| MXPA05003867A (es) | 2002-10-09 | 2005-11-23 | Schering Corp | Tiadiazoldioxidos y tiadiazoloxidos como ligandos de receptor cxc-y cc-quimiocina. |
| CA2504723C (en) * | 2002-11-07 | 2012-10-16 | Abbott Laboratories | Prosthesis with multiple drugs in discrete unmixed droplets |
| US8524148B2 (en) * | 2002-11-07 | 2013-09-03 | Abbott Laboratories | Method of integrating therapeutic agent into a bioerodible medical device |
| US8221495B2 (en) * | 2002-11-07 | 2012-07-17 | Abbott Laboratories | Integration of therapeutic agent into a bioerodible medical device |
| CN101514168B (zh) * | 2003-04-18 | 2014-02-26 | 默沙东公司 | 苯甲酰胺取代的二氧代环丁烯的合成 |
| MY139808A (en) | 2003-12-19 | 2009-10-30 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
| JP4851943B2 (ja) | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
| PE20051093A1 (es) * | 2004-01-30 | 2006-01-16 | Schering Corp | Polimorfos cristalinos de un ligando receptor de cxc quimiocina |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| AU2005241431A1 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
| KR20070011475A (ko) | 2004-05-12 | 2007-01-24 | 쉐링 코포레이션 | Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제 |
| AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| ATE486078T1 (de) | 2005-06-29 | 2010-11-15 | Schering Corp | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors |
| JP2009500334A (ja) | 2005-06-29 | 2009-01-08 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドとしてのジ置換オキサジアゾール |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| MX2008016016A (es) | 2006-06-12 | 2009-02-25 | Schering Corp | Formulaciones y composiciones farmaceuticas de un antagonista selectivo de cxcr2 o cxcr1 y cxcr2 y metodos para usar los mismos para tratar transtornos inflamatorios. |
| CA2657051A1 (en) * | 2006-07-07 | 2008-01-10 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| WO2008148790A1 (en) | 2007-06-06 | 2008-12-11 | Novartis Ag | Anti -inflammatory substituted cyclobutenedione compounds |
| CA2692269A1 (en) * | 2007-07-03 | 2009-01-08 | Schering Corporation | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US20140170112A1 (en) * | 2011-03-12 | 2014-06-19 | Vicus Therapeutics, Llc | Compositions for ameliorating systemic inflammation and methods for making and using them |
| SI2760821T1 (en) | 2011-09-02 | 2018-02-28 | Novartis Ag | A salt salt of an anti-inflammatory substituted cyclobutenedione compound |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| KR101306199B1 (ko) * | 2012-01-31 | 2013-09-09 | 부산대학교 산학협력단 | 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물 |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| WO2019036374A1 (en) | 2017-08-14 | 2019-02-21 | Allergan, Inc. | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND THEIR USE |
| NZ763299A (en) * | 2017-09-14 | 2025-09-26 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| CN111867579B (zh) | 2018-01-08 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 |
| IL281634B2 (en) | 2018-09-21 | 2025-02-01 | Pfizer | Modified diisocyclobutenylamino-3-hydroxy-picolinamide and its use as a CCR6 inhibitor |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| WO2025092968A1 (zh) * | 2023-11-03 | 2025-05-08 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE1669798A1 (de) | 1966-07-28 | 1971-08-26 | Huels Chemische Werke Ag | Verfahren zum Stabilisieren markomolekularer Polyacetale |
| CS214745B2 (en) * | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
| DE2638855C3 (de) | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| DE3309655A1 (de) | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| HU198696B (en) | 1987-01-20 | 1989-11-28 | Nissan Chemical Ind Ltd | Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components |
| JPH02256668A (ja) | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| US5206252A (en) * | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
| GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| US5506252A (en) * | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| DE69507639T2 (de) | 1994-11-16 | 1999-09-02 | American Home Products Corp. | Diaminocyclobuten-3,4-dione |
| AU726858B2 (en) * | 1997-01-23 | 2000-11-23 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| WO1998033763A1 (en) | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| ATE224358T1 (de) | 1998-10-02 | 2002-10-15 | Neurosearch As | Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung |
| DE69922526T2 (de) | 1998-10-08 | 2005-06-02 | Smithkline Beecham Plc, Brentford | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| US6376555B1 (en) * | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
| CA2351464A1 (en) | 1998-12-14 | 2000-06-22 | Joan E. Sabalski | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4 |
| CZ20012185A3 (cs) | 1998-12-16 | 2001-10-17 | Bayer Aktiengesellschaft | Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1220840A2 (en) | 1999-10-15 | 2002-07-10 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| EP1265905A4 (en) | 2000-03-01 | 2003-03-12 | Smithkline Beecham Corp | IL-2 RECEPTOR ANTAGONISTS |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| EP1274415A4 (en) | 2000-03-14 | 2005-09-07 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| EP1284956A4 (en) * | 2000-05-30 | 2005-08-24 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
| US20040132694A1 (en) * | 2001-01-16 | 2004-07-08 | Palovich Michael R. | Il-8 receptor antagonists |
| ES2276926T3 (es) * | 2001-01-16 | 2007-07-01 | Smithkline Beecham Corporation | Antagonistas del receptor de il-8. |
| US20030204085A1 (en) | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| CN1575273A (zh) * | 2001-02-02 | 2005-02-02 | 先灵公司 | 作为cxc趋化因子受体拮抗剂的3.4－二－取代环丁烯－1,2－二酮类化合物 |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| MXPA03009441A (es) * | 2001-04-16 | 2004-02-12 | Schering Corp | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc. |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| JP4836388B2 (ja) | 2002-03-22 | 2011-12-14 | 第一三共株式会社 | ｅＮＯＳ発現に起因する疾患の予防または治療薬 |
| MXPA05003867A (es) | 2002-10-09 | 2005-11-23 | Schering Corp | Tiadiazoldioxidos y tiadiazoloxidos como ligandos de receptor cxc-y cc-quimiocina. |
-
2003
- 2003-03-17 WO PCT/US2003/008287 patent/WO2003080053A1/en not_active Ceased
- 2003-03-17 US US10/390,078 patent/US20040053953A1/en not_active Abandoned
- 2003-03-17 CN CNB038106183A patent/CN100444839C/zh not_active Expired - Fee Related
- 2003-03-17 MX MXPA04009127A patent/MXPA04009127A/es unknown
- 2003-03-17 JP JP2003577881A patent/JP4733350B2/ja not_active Expired - Fee Related
- 2003-03-17 NZ NZ535314A patent/NZ535314A/en not_active IP Right Cessation
- 2003-03-17 EP EP03716685.7A patent/EP1485089B1/en not_active Expired - Lifetime
- 2003-03-17 BR BR0308739-5A patent/BR0308739A/pt not_active IP Right Cessation
- 2003-03-17 CA CA2479126A patent/CA2479126C/en not_active Expired - Fee Related
- 2003-03-17 AU AU2003220384A patent/AU2003220384B2/en not_active Ceased
- 2003-03-18 TW TW096114061A patent/TW200808314A/zh unknown
- 2003-03-18 TW TW092105892A patent/TW200304811A/zh unknown
- 2003-03-18 AR AR20030100943A patent/AR040400A1/es not_active Application Discontinuation
-
2004
- 2004-09-13 ZA ZA200407339A patent/ZA200407339B/en unknown
- 2004-10-15 NO NO20044402A patent/NO20044402L/no not_active Application Discontinuation
-
2007
- 2007-02-14 US US11/705,929 patent/US7960433B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AR040400A1 (es) | 2005-04-06 |
| CA2479126C (en) | 2011-11-15 |
| NZ535314A (en) | 2007-08-31 |
| AU2003220384B2 (en) | 2007-05-10 |
| BR0308739A (pt) | 2005-01-11 |
| JP2005533005A (ja) | 2005-11-04 |
| MXPA04009127A (es) | 2005-01-25 |
| EP1485089A1 (en) | 2004-12-15 |
| TW200304811A (en) | 2003-10-16 |
| US20040053953A1 (en) | 2004-03-18 |
| AU2003220384A1 (en) | 2003-10-08 |
| US20070155756A1 (en) | 2007-07-05 |
| NO20044402L (no) | 2004-12-17 |
| WO2003080053A1 (en) | 2003-10-02 |
| EP1485089B1 (en) | 2013-04-17 |
| CA2479126A1 (en) | 2003-10-02 |
| ZA200407339B (en) | 2005-10-06 |
| TW200808314A (en) | 2008-02-16 |
| CN100444839C (zh) | 2008-12-24 |
| US7960433B2 (en) | 2011-06-14 |
| CN1652779A (zh) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4733350B2 (ja) | ケモカイン媒介疾患の併用治療 | |
| JP6726226B2 (ja) | 複素環式アミンおよびその使用 | |
| CA2350073C (en) | Ccr5 modulators | |
| JP5490723B2 (ja) | Ｎ−アザ二環式カルボキサミド誘導体、これらの調製およびこれらの治療上の使用 | |
| TWI537268B (zh) | 流感病毒複製之抑制劑 | |
| JP6486002B2 (ja) | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド | |
| JP2009542700A (ja) | Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン | |
| JP2012006982A (ja) | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト | |
| WO2014167530A1 (en) | Cannabinoid compounds | |
| EP3943086A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| JP2005534684A (ja) | Ｃｘｃケモカインレセプタ配位子としての３，４−二置換シクロブテン−１，２−ジオン | |
| SK113998A3 (en) | 6-phenylpyridyl-2-amine derivatives | |
| KR20030008151A (ko) | 이미다조피리딘 및 이미다조피리미딘 항바이러스제 | |
| PL200551B1 (pl) | Pochodne 3-(3-izopropylo-5-metylo-4H-1,2,4-triazol-4-ilo)-egzo-8-azabicyklo[3.2.1]oktanu, środek farmaceutyczny, zastosowanie tych pochodnych oraz środka farmaceutycznego i związki pośrednie | |
| CN101711253A (zh) | 用作大麻素受体配体的新化合物 | |
| CN102272111A (zh) | 作为大麻素受体配体的1,2-噻唑基衍生物 | |
| MX2008013208A (es) | Derivados de aminometilpiridina, su preparacion y su aplicacion en terapeutica. | |
| JP2016525573A (ja) | ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸 | |
| KR20240102934A (ko) | 피롤로[2,3-b]피리딘 PGDH 억제제 그리고 제조 및 사용 방법 | |
| KR102128810B1 (ko) | 요산 또는 통풍 질환의 예방 또는 치료 | |
| CN1830445B (zh) | 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物 | |
| CN120569201A (zh) | 用于治疗炎性疾病的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20091008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100105 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100408 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110331 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110422 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |